AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15338802 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment arm
Number of subjects: 519
Study 12052991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial recombinant prourokinase plus intravenous heparin
Number of subjects: 180
Study 12052991 — intervention group
Group type: COMPARATOR
Intervention: Intravenous heparin only
Number of subjects: 180
Study 9883209 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI)
Number of subjects: 350
Study 9883209 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile of Mood States (POMS)
Number of subjects: 350
Study 8520194 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF with sperm treated with pentoxifylline (PF)
Number of subjects: 0
Study 8520194 — intervention group
Group type: EXPERIMENTAL
Intervention: Subzonal sperm insemination (SUZI) with sperm treated with pentoxifylline (PF)
Number of subjects: 0
Study 8520194 — intervention group
Group type: EXPERIMENTAL
Intervention: Micromanipulation by partial zona dissection (PZD) with sperm treated with pentoxifylline (PF)
Number of subjects: 0
Study 8520194 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF with sperm stimulants (PF alone or PF + 2DA)
Number of subjects: 0
Study 8520194 — intervention group
Group type: COMPARATOR
Intervention: SUZI or PZD
Number of subjects: 0
Study 2266066 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline injection in patients with mild spontaneous attacks
Number of subjects: 0
Study 2266066 — intervention group
Group type: COMPARATOR
Intervention: Stable bronchial asthmatic patients
Number of subjects: 0
Study 2266066 — intervention group
Group type: COMPARATOR
Intervention: Atopic patients
Number of subjects: 0
Study 2266066 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with spontaneous attacks
Number of subjects: 0
Study 2266066 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial asthmatic patients having attacks
Number of subjects: 0
Study 2266066 — intervention group
Group type: COMPARATOR
Intervention: Mild and moderate asthmatic subjects
Number of subjects: 0
Study 192560 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg trimeprazine
Number of subjects: 8
Study 192560 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg trimeprazine
Number of subjects: 8
Study 192560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 192560 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal after 10 mg and 20 mg
Number of subjects: 8
Study 31601606 — intervention group
Group type: EXPERIMENTAL
Intervention: ABAaNA EIP (10-modular, peer-facilitated, participatory, community-based programme over 6 months)
Number of subjects: 126
Study 31601606 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 126
Study 29282267 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise programme for 18 weeks, followed by cognitive behavioural therapy, knee brace, or muscle strengthening for 12 weeks if remission is not achieved
Number of subjects: 170
Study 29282267 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise programme for 18 weeks
Number of subjects: 170
Study 29282267 — intervention group
Group type: COMPARATOR
Intervention: Educational material related to OA management
Number of subjects: 170
Study 25403717 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV self-sample kit
Number of subjects: 6000
Study 25403717 — intervention group
Group type: COMPARATOR
Intervention: Further invitation for cytology screening
Number of subjects: 6000
Study 25782319 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with amlodipine and ramipril
Number of subjects: 130
Study 23059151 — intervention group
Group type: EXPERIMENTAL
Intervention: TREA interventions for unmet needs
Number of subjects: 125
Study 23059151 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 125
Study 19888560 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (7.5 mg)
Number of subjects: 57
Study 19888560 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (7.5 mg) plus mifepristone (600 mg)
Number of subjects: 57
Study 19888560 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg)
Number of subjects: 57
Study 19888560 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine plus mifepristone (600 mg)
Number of subjects: 57
Study 17568325 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (150 mg/kg loading dose; 15 mg/kg/hr continuous infusion)
Number of subjects: 8
Study 17568325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 15064264 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial nerve blocked before ulnar nerve (Group I)
Number of subjects: 60
Study 15064264 — intervention group
Group type: COMPARATOR
Intervention: Ulnar nerve blocked before radial nerve (Group II)
Number of subjects: 60
Study 11837735 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg intravenous erythromycin
Number of subjects: 12
Study 11837735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9830087 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure, half-facepiece respirators
Number of subjects: 0
Study 9830087 — intervention group
Group type: EXPERIMENTAL
Intervention: Different brands of respirators
Number of subjects: 0
Study 9830087 — intervention group
Group type: COMPARATOR
Intervention: Ambient exposure levels
Number of subjects: 0
Study 8085933 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily home exercise program aimed at stretching the hamstrings for 4 weeks
Number of subjects: 14
Study 8085933 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 14
Study 29666636 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-mode stimulation (rTMS + tDCS)
Number of subjects: 24
Study 29666636 — intervention group
Group type: COMPARATOR
Intervention: rTMS-only
Number of subjects: 24
Study 27561823 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 214
Study 27561823 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous Laser Ablation (EVLA)
Number of subjects: 214
Study 27561823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy (UGFS)
Number of subjects: 214
Study 24889207 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (6.5 hr in bed per night for five nights)
Number of subjects: 50
Study 24889207 — intervention group
Group type: COMPARATOR
Intervention: Healthy sleep duration (10 hr in bed per night for five nights)
Number of subjects: 50
Study 23002126 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m² day 1 q3W)
Number of subjects: 35
Study 23002126 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine (25 mg/m² day 1 q2W)
Number of subjects: 35
Study 23002126 — intervention group
Group type: COMPARATOR
Intervention: Crossover to Vinorelbine
Number of subjects: 35
Study 23002126 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to Docetaxel
Number of subjects: 35
Study 23002126 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 35
Study 23002126 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine
Number of subjects: 35
Study 20682842 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide
Number of subjects: 24
Study 20682842 — intervention group
Group type: COMPARATOR
Intervention: Bicalutamide
Number of subjects: 24
Study 18171294 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ART and IL-2 therapy
Number of subjects: 0
Study 18171294 — intervention group
Group type: COMPARATOR
Intervention: ART alone
Number of subjects: 0
Study 16983001 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone
Number of subjects: 80
Study 16983001 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% calcipotriol
Number of subjects: 80
Study 16983001 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% pimecrolimus
Number of subjects: 80
Study 16983001 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 80
Study 12679754 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 12679754 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel + Aspirin
Number of subjects: 0
Study 10764713 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal fat perfusion
Number of subjects: 12
Study 10764713 — intervention group
Group type: EXPERIMENTAL
Intervention: Long chain fatty acids
Number of subjects: 12
Study 10764713 — intervention group
Group type: COMPARATOR
Intervention: Medium chain fatty acids
Number of subjects: 12
Study 10764713 — intervention group
Group type: COMPARATOR
Intervention: Loxiglumide (CCK-A receptor antagonist) with long chain fatty acids
Number of subjects: 12
Study 8612393 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 mg/kg methylnaltrexone plus 0.05 mg/kg morphine
Number of subjects: 12
Study 8612393 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg morphine
Number of subjects: 12
Study 8612393 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 0.05 mg/kg morphine
Number of subjects: 12
Study 1483498 — intervention group
Group type: EXPERIMENTAL
Intervention: tetracycline coadministration with mefloquine
Number of subjects: 20
Study 1483498 — intervention group
Group type: COMPARATOR
Intervention: mefloquine alone
Number of subjects: 20
Study 3881608 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss group (mean loss of 4.5 kg [10 lb])
Number of subjects: 496
Study 3881608 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-restriction group (mean reduction of 40 mEq/day)
Number of subjects: 496
Study 3881608 — intervention group
Group type: COMPARATOR
Intervention: Control group (discontinued medication without dietary intervention)
Number of subjects: 496
Study 3881608 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoverweight mild hypertensives with sodium restriction
Number of subjects: 496
Study 3881608 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight mild hypertensives with weight reduction
Number of subjects: 496
Study 29229466 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 57
Study 29229466 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous electrocoagulation (EC)
Number of subjects: 57
Study 29229466 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EC and RFA
Number of subjects: 57
Study 27394382 — intervention group
Group type: EXPERIMENTAL
Intervention: High vegetable and fiber, low-fat diet with daily physical activity goals
Number of subjects: 0
Study 27394382 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 0
Study 25898404 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking in a forested area
Number of subjects: 0
Study 25898404 — intervention group
Group type: COMPARATOR
Intervention: Urban environment (control)
Number of subjects: 0
Study 23623622 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent aide plus case management services
Number of subjects: 138
Study 23623622 — intervention group
Group type: COMPARATOR
Intervention: Case management services only
Number of subjects: 138
Study 20671550 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol 320
Number of subjects: 60
Study 20671550 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol 370
Number of subjects: 60
Study 28679467 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2339345
Number of subjects: 16
Study 28679467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16722866 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antifungal nail lacquer (ciclopirox 8%)
Number of subjects: 70
Study 16722866 — intervention group
Group type: COMPARATOR
Intervention: Self-inspection instructions alone (NAFL)
Number of subjects: 70
Study 12848775 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg x m(‐2) with zosuquidar 3HCl
Number of subjects: 43
Study 12848775 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 225 mg x m(‐2) with zosuquidar 3HCl
Number of subjects: 43
Study 12848775 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 175 mg x m(‐2) alone
Number of subjects: 43
Study 10535716 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) administered at home (0.1 mL per kg body weight subcutaneously twice daily)
Number of subjects: 294
Study 10535716 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin administered in hospital
Number of subjects: 294
Study 10535716 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous calcium heparin (SCHep) administered at home (0.5 mL bid)
Number of subjects: 294
Study 10535716 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 294
Study 10535716 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 294
Study 10535716 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous calcium heparin (SCHep)
Number of subjects: 294
Study 8559429 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IgIV) treatment
Number of subjects: 100
Study 8559429 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) treatment
Number of subjects: 100
Study 8559429 — intervention group
Group type: COMPARATOR
Intervention: Hospital control group (subarachnoid hemorrhage)
Number of subjects: 100
Study 1988416 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 155
Study 1988416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 6840181 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous melphalan (10 mg)
Number of subjects: 6
Study 6840181 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melphalan (10 mg)
Number of subjects: 6
Study 29652273 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone infusion 0.5 μg/kg/min without a loading dose followed by 0.5‐0.75 μg/kg/min
Number of subjects: 116
Study 29652273 — intervention group
Group type: COMPARATOR
Intervention: Milrinone infusion with loading dose 50 μg/kg over 10 min followed by 0.5‐0.75 μg/kg/min
Number of subjects: 116
Study 27338218 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-ED milk (3.25% fat)
Number of subjects: 125
Study 27338218 — intervention group
Group type: EXPERIMENTAL
Intervention: 150% portion of milk (275 g)
Number of subjects: 125
Study 27338218 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-ED milk (3.25% fat) with increased portion size
Number of subjects: 125
Study 24844029 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Perforated Membrane (MPM)
Number of subjects: 15
Study 24844029 — intervention group
Group type: COMPARATOR
Intervention: Occlusive Membrane (OM)
Number of subjects: 15
Study 22045830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide 1 mg intravenously
Number of subjects: 15
Study 20045196 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone
Number of subjects: 0
Study 18951420 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser with 250 mJ, 62.5 J/cm2, combined with 2 Hz
Number of subjects: 91
Study 18951420 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser with 250 mJ, 62.5 J/cm2, combined with 3 Hz
Number of subjects: 91
Study 18951420 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser with 250 mJ, 62.5 J/cm2, combined with 4 Hz
Number of subjects: 91
Study 18951420 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser with 350 mJ, 87.5 J/cm2, combined with 2 Hz
Number of subjects: 91
Study 18951420 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser with 350 mJ, 87.5 J/cm2, combined with 3 Hz
Number of subjects: 91
Study 18951420 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser with 350 mJ, 87.5 J/cm2, combined with 4 Hz
Number of subjects: 91
Study 18951420 — intervention group
Group type: COMPARATOR
Intervention: High‐speed handpiece (control)
Number of subjects: 91
Study 18951420 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 91
Study 16926775 — intervention group
Group type: EXPERIMENTAL
Intervention: saquinavir SGC/ritonavir (1600 mg/100 mg)
Number of subjects: 171
Study 16926775 — intervention group
Group type: COMPARATOR
Intervention: efavirenz (600 mg)
Number of subjects: 171
Study 14700451 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study 14700451 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10769437 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol (0.5‐1.0 microgram, mean = 0.54 +/‐ 0.03 microgram)
Number of subjects: 41
Study 10769437 — intervention group
Group type: COMPARATOR
Intervention: Control group (500 mg calcium daily)
Number of subjects: 41
Study 9345173 — intervention group
Group type: COMPARATOR
Intervention: Control group (after delivery supplementation)
Number of subjects: 2047
Study 8315266 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal oral glucose supplementation
Number of subjects: 16
Study 8315266 — intervention group
Group type: COMPARATOR
Intervention: Water (placebo)
Number of subjects: 16
Study 2961314 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial (I.A.) 5-fluorodeoxyuridine (FUDR)
Number of subjects: 64
Study 2961314 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (I.V.) 5-fluorodeoxyuridine (FUDR)
Number of subjects: 64
Study 2961314 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial (I.A.) 5-fluorodeoxyuridine (FUDR) in patients with negative hepatic lymph nodes
Number of subjects: 64
Study 29272753 — intervention group
Group type: EXPERIMENTAL
Intervention: Four or more Elixhauser Comorbidity Index (ECI) conditions
Number of subjects: 777
Study 29272753 — intervention group
Group type: EXPERIMENTAL
Intervention: Any one of a subset of ECI conditions
Number of subjects: 777
Study 29272753 — intervention group
Group type: COMPARATOR
Intervention: Aboriginal cases with four or more ECI conditions
Number of subjects: 777
Study 29272753 — intervention group
Group type: COMPARATOR
Intervention: Aboriginal cases with subset of ECI conditions
Number of subjects: 777
Study 26427784 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus infiltration technique
Number of subjects: 20
Study 26427784 — intervention group
Group type: COMPARATOR
Intervention: Lateral sinus lift
Number of subjects: 20
Study 24586492 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory suppression during recall tasks
Number of subjects: 0
Study 24586492 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory recall tasks
Number of subjects: 0
Study 24586492 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaborative recall of paired-associates
Number of subjects: 0
Study 24586492 — intervention group
Group type: EXPERIMENTAL
Intervention: Task goals requiring recall
Number of subjects: 0
Study 22693269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide (NO2) exposure (400 ppb for 1 hour)
Number of subjects: 0
Study 22693269 — intervention group
Group type: COMPARATOR
Intervention: Air (control group)
Number of subjects: 0
Study 20167461 — intervention group
Group type: EXPERIMENTAL
Intervention: Hop extract (100 mug 8‐prenylnaringenin per day)
Number of subjects: 36
Study 20167461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17307809 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (clamped at 3 minutes after delivery)
Number of subjects: 37
Study 17307809 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping (clamped within 30 seconds)
Number of subjects: 37
Study 15790430 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy (LPS)
Number of subjects: 122
Study 15790430 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy (LPT)
Number of subjects: 122
Study 11840379 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic renal insufficiency
Number of subjects: 15
Study 10341676 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal with 12% MUFA / 17% SFA
Number of subjects: 15
Study 10341676 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal with 17% MUFA / 12% SFA
Number of subjects: 15
Study 10341676 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal with 24% MUFA / 5% SFA
Number of subjects: 15
Study 7499981 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement sealer (Ketac‐Endo)
Number of subjects: 378
Study 1958764 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG sleep profiles during the first REM period of the recurrent episode
Number of subjects: 32
Study 1958764 — intervention group
Group type: COMPARATOR
Intervention: Previous episode of depression
Number of subjects: 32
Study 7044608 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management with early intensive therapy including nitrates and beta-blocking agents
Number of subjects: 0
Study 7044608 — intervention group
Group type: COMPARATOR
Intervention: Urgent surgery
Number of subjects: 0
Study 7044608 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 0
Study 7044608 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective surgery
Number of subjects: 0
Study 31273863 — intervention group
Group type: COMPARATOR
Intervention: Strength Training on Stable Surfaces (ST)
Number of subjects: 64
Study 31273863 — intervention group
Group type: COMPARATOR
Intervention: Strength Training on Unstable Surfaces (UST)
Number of subjects: 64
Study 31273863 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 64
Study 28961826 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 329
Study 28961826 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy (WBRT) among NSCLC patients
Number of subjects: 329
Study 26073393 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 47
Study 26073393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 26073393 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily
Number of subjects: 47
Study 26073393 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (unspecified)
Number of subjects: 47
Study 26073393 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength and resting respiratory exchange ratio (RER)
Number of subjects: 47
Study 24935203 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 111